Immunoglobulin Market
Number of pages: 100 | Report Format: PDF | Published date: August 25, 2022
Historical Years – 2023 | Base Year – 2023 | Forecasted Years – 2024-2032
|
Report Attribute |
Details |
|
Market size value in 2023 |
US$ 14.32 billion |
|
Revenue forecast in 2032 |
US$ 26.5 billion |
|
Growth Rate |
CAGR of 7.1% from 2024-2032 |
|
Base year for estimation |
2023 |
|
Forecast period |
2024-2032 |
|
Segments covered |
Products, Application, Route Of Administration |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global immunoglobulin market was valued at US$ 14.32 billion in 2023 and is expected to register a revenue CAGR of 7.1% to reach US$ 26.5 billion by 2032.
Market Fundamentals
Plasma cells produce glycoproteins known as immunoglobulins (Ig) or antibodies. Plasma cells are protein-producing cells participating in humoral immune responses to bacteria, viruses, fungi, parasites, cellular antigens, chemicals, and synthetic substances. Immunoglobulins account for about 20% of the protein in plasma. Immunoglobulins are Y-shaped proteins the immune system uses to neutralize the effect of any foreign material, such as viruses, bacteria, or pathogens. The plasma cells naturally produce these antibodies in natural defenses, which help fight infections and diseases. When exposed to antigens, active plasma and B cells generate immunoglobulins. These molecules are released in response to antigen exposure, enabling the immune system to detect and respond to various diseases.
Many ailments, including primary and secondary immunodeficiency diseases, neuromuscular illnesses, and Kawasaki disease, have been treated using immunoglobulin. Antibodies or immunoglobulins comprise two light chains and two heavy chains arranged in a light-heavy-heavy-light structure. The heavy chains differ by class. They have one ‘Fc’ region that mediates biological functions (for example, binding to cellular receptors) and a ‘Fab’ region that contains antigen-binding sites. All antibodies perform one or more functions (bifunctional), such as activating the complement system, opsonizing microbes for easy phagocytosis, preventing microbes from attaching to mucosal surfaces and neutralizing toxins and viruses.
Market Dynamics
The immunoglobulin market is expanding due to the availability of reimbursement policies and increased awareness, which leads to increased adoption. Reimbursement policies are important in increasing patient access by reducing financial barriers. Furthermore, increasing awareness of the efficacy of immunoglobulin therapies and their applications in various medical conditions leads to greater acceptance among healthcare professionals and patients. Increased awareness and supportive reimbursement frameworks create a favorable environment for immunoglobulin adoption, driving sustained market growth.
Sedentary lifestyle habits, such as the consumption of saturated fats, excessive salt, and sweets, decreased physical activity, and high alcohol consumption, are contributing to the rise in the occurrence of immunodeficiency disorders. As a result, the increasing prevalence of lifestyle-related illnesses such as obesity and conditions caused by inadequate antibody production is expected to accelerate market growth. According to a report from the National Institute of Health, there are over 200 different types of primary immune deficiency diseases (PIDDs), which affect approximately 500,000 people in the US alone. As a result, the demand for immunoglobulin therapy increases the prevalence of both primary and acquired immunodeficiency disorders.
The immunoglobulin industry faces challenges due to its complex manufacturing processes and reliance on a consistent supply of plasma or alternative sources for antibody production. Intricate manufacturing presents production challenges, potentially causing supply chain disruptions. Also, high treatment costs present a significant barrier to patient access and market growth. This affordability issue raises concerns about equal access to immunoglobulin therapies, limiting their widespread use. However, high costs for medications and side effects related to immunoglobulins may be a restraining factor for the global immunoglobulin market.
Market Ecosystem
The global immunoglobulin market has been analyzed from four perspectives: by products, applications, route of administration, and region.
Global Immunoglobulin Market by Products
Based on products, the global immunoglobulin market is segmented into immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE), Immunoglobulin D (IgD).
The IgG immunoglobulin protects against bacterial and viral infections. IgA keeps immunological homeostasis with the microbiota and protects the mucosal tissues against microbial invasion. IgM antibodies play a crucial role in immune control and immunological tolerance. In addition, it also acts as the first line of defense against infections for the host. The immune system secretes immunoglobulin E to show hypersensitivity.
The IgG immunoglobulin protects against bacterial and viral infections. In comparison, IgA's role is to keep immunological homeostasis with the microbiota and protect the mucosal tissues against microbial invasion. Similarly, IgM antibodies are crucial for immune control and immunological tolerance. In addition, it also acts as the first line of defense against infections for the host. The immune system secretes immunoglobulin E to show hypersensitivity.
Global Immunoglobulin Market by Applications
According to applications, the global immunoglobulin market is segmented into hypogammaglobulin, CIDP (Chronic Inflammatory Demyelinating Polyneuropathy), immunodeficiency diseases, and myasthenia gravis.
The Hypogammaglobulinemia segment has dominated the market. Hypogammaglobulinemia is a disorder characterized by low serum immunoglobulin or antibody levels. Immunoglobulins are the primary components of the humoral immune system, capable of recognizing antigens and triggering a biological response to eliminate the infectious source. The most common primary immunodeficiency is hypogammaglobulinemia, which accounts for most immunocompromised patients. It can be diagnosed either in childhood or in adulthood. Primary hypogammaglobulinemia usually begins in the second to third decade of life, but clinical signs can appear at any age. Previously, a bimodal distribution was observed, with frequent diagnoses between the ages of 6 and 10 and 20 to 40. Hypogammaglobulinemia limits the production of antibodies. This disease develops because of an infection caused by an autoimmune condition or a cancer like multiple myeloma. Immunoglobulins are the first line of treatment for CIDP (chronic inflammatory demyelinating polyneuropathy). Immunodeficiency illness treatment requires a sustained supply of immunoglobulin to lower the frequency and severity of infections.
Global Immunoglobulin Market by Route of Administration
Based on the route of administration, the global immunoglobulin market is segmented into intravenous and subcutaneous.
The intravenous segment has accounted for the largest revenue share in the global market, as intravenous immunoglobulins are considered the first line of treatment. The method ensures that medications, such as immunoglobulins, are delivered quickly and accurately into the bloodstream, increasing bioavailability and treatment efficacy. Additionally, it is used to raise the level of platelets in the blood and help prevent certain infections with B-cells. Compared to intravenous treatment, immunoglobulin subcutaneous delivery is linked to a lower risk of systemic and localized danger. However, the subcutaneous segment is expected to have the fastest CAGR during the forecast period. This increase is attributed to various factors, including advancements in subcutaneous delivery technologies, a growing patient preference for at-home treatments, and the development of more convenient and user-friendly administration methods.
Global Immunoglobulin Market by Region
The global immunoglobulin market has been segmented based on region into North America, Europe, Asia Pacific, and the Rest of the World.
The main contributor to the worldwide immunoglobulin market is North America. The high frequency of neurological and immunological illnesses in this region is one of the factors promoting the growth of the immunoglobulin market. For instance, Myasthenia Gravis (MG), an autoimmune neurological disorder, is characterized by impaired transmission at the neuromuscular junction, according to NCBI (National Center for Biotechnology Information) in May 2021. The incidence ranges from 4.1 to 30 occurrences per million person-years, whereas the prevalence rate fluctuates between 150 and 200 cases per million. Asia-Pacific is expected to grow at a profitable rate during the forecast period. Drug companies are also investing in cutting-edge therapies like antibody-drug conjugates, to provide innovative treatments projected to boost market expansion in the upcoming years.
Competitive Landscape
Some of the prominent players operating in the global immunoglobulin market are: -
Strategic Developments
The growing demand for the Immunoglobulin market is due to increased usage of immunoglobulins in medical treatments.
2. Which are the key companies operating in the Immunoglobulin market? Some prominent players operating in the global immunoglobulin market are ADMA Biologics Inc., Baxter International Inc., and Biotest AG., among others.
The market is expected to witness a CAGR of 7.1 % during the forecast period.
North America accounted for most of the global immunoglobulin market, with the majority of the market.
Restraining factors in the global immunoglobulin market include its complex manufacturing processes and reliance on a consistent supply of plasma or alternative sources for antibody production.
Table of Content
*Insights on financial performance are subject to the availability of information in the public domain
List of Tables
List of Figures
Recommended Reports